We were delighted to speak with Prof. Erika Petersen (University of Arkansas for Medical Sciences, Little Rock, AR, USA) around the six month results from the SENZA-PDN study.
The abstract entitled: ‘Sustained Benefits for 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy—Six Month Results from a Multicenter Randomized Controlled Trial’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
- What are the unmet needs in the treatment of patients with painful diabetic neuropathy? (00:13)
- What evidence supports the use of 10 kHz spinal cord stimulation? (1:10)
- Could you tell us a little about the SENZA-PDN study and its findings? (2:24)
- What will be the clinical impact of these findings? (3:46)
- Which patients are likely to benefit most from this treatment? (5:19)
Disclosures: SENZA PDN study is sponsored by Nevro, Inc and registered at Clinicaltrials.gov. Dr Petersen has received research support from Medtronic, Neuros Medical, Nevro Corp, and ReNeuron as well as personal fees from Nevro, Abbott Neuromodulation, Medtronic Neuromodulation, and Neuros Medical.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Reference: Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy. JAMA Neurol. 2021; doi: 10.1001/jamaneurol.2021.0538.
Share this Video
Related Videos In Neuropathic Pain
Erika Petersen, AAN 2021: Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy
We were delighted to speak with Prof. Erika Petersen (University of Arkansas for Medical Sciences, Little Rock, AR, USA) around the six month results from the SENZA-PDN study. The abstract entitled: ‘Sustained Benefits for 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy—Six Month Results from a Multicenter Randomized Controlled Trial’ was presented at […]
Raili Kauppinen, EAN 2020 – ENVISION Study in Patients With Acute Hepatic Porphyria
Raili Kauppinen (University Hospital of Helsinki, Finland) shares key findings and insights into the ENVISION study, which evaluated the efficacy and safety of givosiran, a subcutaneously administered RNA interference therapeutic targeting aminolevulinic acid synthase 1, in patients with acute hepatic porphyrias (ClinicalTrials.gov Identifier: NCT03338816). Questions 1. Could you give us a brief overview of acute […]
Nadine Attal, EAN 2020 – Therapeutic Cannabis: Is It Really Helpful for Neuropathic Pain?
Nadine Attal (University Versailles Saint Quentin, Versailles, France) shared with us her expert opinion on the controversial topic of therapeutic cannabis for neuropathic pain. Questions 1. What advantages does cannabis offer compared to current pharmacological treatments for neuropathic pain? (0:05) 2. What can we conclude about the clinical evidence to date? (0:41) 3. What have […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!